艾里德克斯 IRIX 深 沪
等待开盘 10-12 09:30:00 美东时间
0.89
-0.008
-0.89%
华盛通- 最 高0.922
- 今 开0.922
- 成交量 20.32万股
- 最 低 0.8126
- 昨 收 0.898
- 总市值 1563.28万
- 52周最高 1.6481
- 市盈率 静 --
- 换手率 1.16%
- 52周最低 0.607
- 委 比 -91.86%
- 总股本 1756.49万
- 历史最高 16.64
- 量 比 0.05
- 振 幅 12.18%
- 历史最低 0.607
- 每 手 1
- 风险率 0.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Iridex Announces Publication Of 2-Yr Clinical Study Demonstrating Favorable Outcomes With TLT Using MicroPulse Technology In Patients With Primary Glaucoma
Iridex Corporation (NASDAQ:IRIX), a worldwide leader in innovative laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced the publication of a two-year clinical study demonstrating favorable outcomes with transscleral laser ...
46分钟前
Iridex Completes Relocation of Manufacturing Facility to San Jose, California
Iridex Corporation has successfully relocated its manufacturing facility from Mountain View to San Jose, California, expecting to save approximately $600,000 annually. CEO Patrick Mercer highlighted the move as a key cost-saving measure and a step towards improved operational efficiency and future growth. The relocation aligns with the company's strategy to enhance profitability and prepare for future business needs.
10-05 11:00
Iridex shares are trading lower after the company reported worse-than-expected Q2 financial results.
Iridex shares are trading lower after the company reported worse-than-expected Q2 financial results.
08-19 22:46
Iridex Affirms FY2026 Sales Guidance of $51.000M-$53.000M vs $53.227M Est
Iridex (NASDAQ:IRIX) affirms FY2026 sales outlook from $51.000 million-$53.000 million to $51.000 million-$53.000 million vs $53.227 million estimate.
08-19 04:09
Iridex Q2 EPS $(0.07) Misses $(0.01) Estimate, Sales $12.566M Miss $13.587M Estimate
Iridex (NASDAQ:IRIX) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.01) by 600 percent. This is a 16.67 percent decrease over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $12.566 million which m...
08-19 04:06
IRIDEX (IRIX) 2026财年第二季度业绩电话会议：G6增长与正向现金流
IRIDEX 2026财年第二季度营收下降7%至1260万美元，而Cyclo-G6营收增长19%。管理层重申了5100万至5300万美元的业绩指引。
08-18 23:51
IRIDEX (IRIX) Q2 2026 Earnings Call: G6 Growth and Positive Cash Flow
IRIDEX Q2 2026 revenue fell 7% to $12.6 million, while Cyclo-G6 revenue grew 19%. Management reaffirmed its $51 million-$53 million outlook.
08-18 23:50
Iridex Expands Its EyeProGPO Product Offering To Include The Company’s Line Of EndoProbe Handpieces
Through the agreement, more than 4,300 EyeProGPO members will have access to preferred pricing on Iridex EndoProbe Handpieces, expanding the value Iridex provides to ophthalmology practices, ambulatory surgery centers, and hospitals across the United States. The addition builds on Iridex’s existing ...
07-20 19:14
Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering
Iridex Corporation expands its EyeProGPO product offering to include its EndoProbe® Handpieces, providing over 4,300 EyeProGPO members with preferred pricing. The addition enhances access to Iridex's retina laser portfolio for ophthalmology practices and surgical centers. The EndoProbe Handpieces are single-use devices for treating retinal disorders, available in various configurations. Both Iridex and EyeProGPO emphasize their commitment to adva...
07-20 11:00
Iridex Adjourns 2026 Annual Meeting, Plans July Reconvening
Iridex ( ($IRIX) ) has provided an announcement. On June 12, 2026, Iridex Corpo...
06-19 04:33
